Berobenatide
A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)
Pfizer · Phase 3 · Recruiting · Enrollment 756
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Placebo | n/r | n/r | n/r | n/r |
| Arm 1: Berobenatide Once Weekly | n/r | n/r | n/r | n/r |
| Arm 2: Berobenatide Once Weekly | n/r | n/r | n/r | n/r |
| Arm 3: Berobenatide Once Weekly | n/r | n/r | n/r | n/r |
Not shown
- Placebo: endpoint not reported
- Arm 1: Berobenatide Once Weekly: endpoint not reported
- Arm 2: Berobenatide Once Weekly: endpoint not reported
- Arm 3: Berobenatide Once Weekly: endpoint not reported